F M Investments LLC Invests $3.69 Million in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

F M Investments LLC acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 61,782 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,686,000.

Several other large investors have also recently added to or reduced their stakes in ANIP. James Investment Research Inc. purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at $243,000. New York State Teachers Retirement System boosted its position in ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in ANI Pharmaceuticals by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 1,582 shares in the last quarter. State of Alaska Department of Revenue increased its position in ANI Pharmaceuticals by 5.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock worth $564,000 after purchasing an additional 464 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in shares of ANI Pharmaceuticals by 3.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock worth $477,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ANIP. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Finally, HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $58.19 on Friday. The firm has a market capitalization of $1.22 billion, a PE ratio of 49.74 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The firm’s fifty day simple moving average is $59.13 and its 200 day simple moving average is $61.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm’s revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.06 EPS. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.51 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.